http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
-
Sanofi acquires rights to plozasiran drug candidate in Greater China
-
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
-
Arrowhead receives $100 million milestone from Sarepta for ARO-DM1 study
-
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results
-
Arrowhead starts phase 3 trial for rare cholesterol disorder drug
-
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
-
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
-
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
-
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
-
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results
-
Arrowhead Pharmaceuticals Inc. (ARWR) Appoints Daniel Apel as CFO
-
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals (ARWR) Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
-
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
-
Arrowhead Pharmaceuticals Inc. (ARWR) Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
-
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
-
Arrowhead Pharmaceuticals Inc. (ARWR) expands resources for those affected by FCS
-
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
-
Arrowhead Pharmaceuticals (ARWR) Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
-
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
-
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
-
Arrowhead Pharmaceuticals (ARWR) Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics (SRPT)
-
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results
-
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
-
Arrowhead Pharmaceuticals Inc. (ARWR) Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7
-
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
-
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
-
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
-
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
-
Arrowhead Pharmaceuticals Inc. (ARWR) Submits New Drug Application to U.S. FDA for Plozasiran
-
Arrowhead Pharmaceuticals (ARWR) Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
-
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
-
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
-
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
-
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals (ARWR) Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
-
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
